Tag Archives: NASDAQ:CBAY

Oppenheimer Maintains a Buy Rating on CymaBay Therapeutics (CBAY)

Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $9.77. Olson commented: “Seladelpar (PPARδ agonist) received Breakthrough Therapy Designation (BTD)

CymaBay Therapeutics (CBAY) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Eliana Merle from Cantor Fitzgerald reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $20. The company’s shares closed yesterday at $8.70. Merle commented: “. Reiterate our Overweight

Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (NASDAQ: CBAY) and Lipocine (NASDAQ: LPCN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CymaBay Therapeutics (CBAY – Research Report) and Lipocine (LPCN – Research Report) with bullish sentiments. CymaBay Therapeutics (CBAY) In a report released

CymaBay Therapeutics (CBAY) Received its Third Buy in a Row

After Cantor Fitzgerald and Oppenheimer gave CymaBay Therapeutics (NASDAQ: CBAY) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on CymaBay Therapeutics today and set a price

CymaBay Therapeutics (CBAY) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson reiterated a Buy rating on CymaBay Therapeutics (NASDAQ: CBAY) yesterday and set a price target of $20. The company’s shares closed yesterday at $11.64. Olson said: “CBAY reported 2Q financial results and provided a business update

CymaBay Therapeutics (CBAY) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on CymaBay Therapeutics (NASDAQ: CBAY) yesterday and set a price target of $16. The company’s shares closed yesterday at $11.64. Tanner commented: “: We reiterate the Overweight rating and 12-month PT